Thu, February 17, 2022

Patrick Donnelly Maintained (TXG) at Strong Buy with Decreased Target to $150 on, Feb 17th, 2022

Patrick Donnelly of Citigroup, Maintained "10x Genomics, Inc." (TXG) at Strong Buy with Decreased Target from $175 to $150 on, Feb 17th, 2022.

Patrick has made no other calls on TXG in the last 4 months.



There is 1 other peer that has a rating on TXG. Out of the 1 peers that are also analyzing TXG, 0 agree with Patrick's Rating of Hold.



This is the rating of the analyst that currently disagrees with Patrick


  • Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $205 on, Thursday, November 4th, 2021